StockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to “Hold”

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

A number of other equities research analysts have also recently commented on ABEO. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Stock Down 0.4 %

Shares of ABEO stock opened at $5.61 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01. The company’s fifty day moving average price is $6.08 and its 200-day moving average price is $5.58. The company has a market capitalization of $243.87 million, a price-to-earnings ratio of -2.09 and a beta of 1.44.

Hedge Funds Weigh In On Abeona Therapeutics

Several large investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in Abeona Therapeutics during the 3rd quarter valued at about $84,000. Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics during the third quarter valued at approximately $151,000. XTX Topco Ltd purchased a new stake in shares of Abeona Therapeutics in the third quarter worth approximately $160,000. JPMorgan Chase & Co. lifted its stake in shares of Abeona Therapeutics by 74.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 28,606 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Abeona Therapeutics by 54.3% during the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 33,831 shares during the period. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.